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ABSTRACT 
BACKGROUND: Prostate-specific antigen (PSA) screening and concomitant treatment can be 
implemented in several ways. We investigated how the net benefit of PSA screening varies between 
common practice versus “good practice.” 
METHODS: We used MIcrosimulation SCreening ANalysis (MISCAN) to evaluate the effect on 
quality-adjusted life-years (QALYs) if 4 recommendations were followed: limited screening in older 
men; selective biopsy in men with elevated PSA; active surveillance for low-risk tumors; and 
treatment preferentially delivered at high-volume centers. Outcomes were compared to a base 
model with annual screening starting at ages 55–69, simulated using the European Randomized 
Study of Screening for Prostate Cancer (ERSPC) data.  
RESULTS: In terms of QALYs gained compared to no screening, per 1000 screened men followed 
over their lifetime, recommended good practice led to 73 life-years (LYs) and 74 QALYs gained 
compared to 73 LYs and 56 QALYs for the base model. In contrast, common practice led to 78 LYs 
gained but only 19 QALYs gained; more than a 75% relative reduction in QALYs gained from 
unadjusted LYs gained. The poor outcomes for common practice were influenced predominantly by 
use of aggressive treatment for low-risk disease, with PSA testing in older men also strongly 
reducing potential QALY gains. 
CONCLUSIONS: Commonly-used PSA screening and treatment practices are associated with little 
net benefit. Following a few straightforward clinical recommendations, particularly greater use of 
active surveillance for low-risk disease and reducing screening in older men, would lead to an 
almost 4-fold increase in the net benefit of prostate cancer screening. 
Keywords (MeSH): Prostate-Specific Antigen/blood, Prostatic Neoplasms, Mass Screening, Quality-
of-Life, Quality-Adjusted-Life-Years, Early Detection of Cancer/adverse effects  
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INTRODUCTION 
The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated that 
regular prostate-specific antigen (PSA) screening every 2-4 years leads to a relative reduction in 
prostate cancer (PC)-specific mortality of 21% at 13 years of follow-up.1 However, this benefit is 
offset by harms, in terms of over-diagnosis and consequent side-effects from treatment, hence the 
clear recommendation against PSA screening from the United States Preventive Services Task Force 
in 2012.2 Using MIcrosimulation SCreening ANalysis (MISCAN), we have previously shown that over 
a lifetime, screening leads to a 28% relative reduction in PC-specific mortality and 8.4 life-years 
gained per averted death.3 However, this benefit is mitigated by a loss in quality-adjusted life-years 
(QALYs)—a 23% reduction from life-years gained—primarily because of side-effects of treatment 
such as urinary and erectile dysfunction.3 
There have been considerable advances in our understanding of PC and PSA since the ERSPC 
was initiated in the early 1990s. Empirical data suggest that the ratio of benefit-to-harm could be 
improved by restricting screening to appropriate age ranges, restricting biopsy and treatment to 
men at highest risk, and shifting treatment to higher-volume centers.4-6 These relatively 
uncontroversial findings have been incorporated in many guidelines. In contrast, research into 
common clinical practice has found frequent PSA testing among older men with limited life 
expectancy,7-8 aggressive use of curative treatment for low-risk tumors,9 and surgical treatment 
largely performed by low-volume providers.10 
We hypothesize that the benefit-to-harm ratio from PSA screening and subsequent 
treatment would be improved by following a straightforward set of simple good practice guidelines. 
We sought to quantify the effects of implementing these recommendations upon the outcomes of 
PC screening using MISCAN. We compared a “recommended good practice” model versus a model 
reflecting common screening and treatment practices, with a base model using ERSPC data. 
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METHODS 
MISCAN 
The MISCAN model, described in detail elsewhere,3 simulates individual life histories with and 
without PSA screening, and with and without development of PC. The “tumor growth model” 
simulates PC natural history, which progresses from no disease, to preclinical screen-detectable PC, 
to clinical cancer at various stages. Thereafter, the tumor is screen-detected, clinically diagnosed, or 
progresses to another stage. The model is calibrated using raw data from the core age group (55–
69 years) of the Rotterdam and Göteborg sections of the ERSPC.  This includes follow-up data 
through 2008 (median 11 years) and a stage-dependent cure rate estimated for the observed PC-
specific mortality reduction of 29% among attendees to screening in ERSPC.3 The model was 
subsequently validated using data from all centra in the ERSPC, for both the screening and the 
control arms (thus accounting for a low contamination rate), as described earlier.3 
The effectiveness of radical prostatectomy (RP) compared to watchful waiting was assigned 
a relative risk of PC-specific mortality of 0.65 based on Scandinavian Prostate Cancer Group-4 
data11; a similar effect was assumed for radiotherapy (RT). Survival was modeled using the Gleason 
score−dependent Albertsen data12 as well as Surveillance, Epidemiology, and End Results (SEER) 
data.3  
QALYs were calculated by multiplying utility estimates for various health states, where 0 is 
death (or worst imaginable health) and 1 is full health, by the duration and number of men in the 
state. Utility estimates were obtained from the Cost-Effectiveness Analysis Registry13 or the 
literature, or were based on assumptions. For active surveillance (AS), we assumed an estimated 
utility of 0.97 for the base case. A complete justification and references to the assumptions used in 
the base model were reported previously.3  
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Model building 
MISCAN relies on certain parameter inputs, which can be changed. We simulated lifetime outcomes 
for those who underwent PSA screening versus controls who did not undergo screening, for a male 
population aged 0 to 100 years, with an age distribution based on the European Standard 
Population.3 We changed some of MISCAN’s inputs to investigate the effects of the different 
models upon QALYs.  
 The base model uses annual PSA screening, as often practiced in the U.S. It follows a 
population of men aged 0–100 over their lifetimes and screens them, with 80% participation rate, 
between ages 55 and 69; matching the ERSPC core age group where a significant effect on PC-
specific mortality was demonstrated in favor of screening.1, 14-15 The base model also uses: positive 
predictive value (PPV) of biopsy of 22.7% as in the ERSPC; primary treatment distribution (RP, RT, or 
AS with deferred treatment) based on age, T-stage and Gleason score as in the ERSPC; and 
complication rates after curative treatment as seen in U.S. population-based series.3 
We created 2 additional models: “recommended good practice,” which amended the base 
model by incorporating 4 simple recommendations on screening and treatment found in many 
guidelines, and “common practice,” in which we incorporated data from empirical studies of 
contemporary U.S. practice patterns. Table 1 lists the assumptions changed from the base model.  
Age for screening. The ERSPC found no evidence of benefit for men who start PSA screening 
at age ≥70, with the lower bound of the 95% CI excluding the central estimate for risk reduction for 
men aged <70.15 Similarly, the American Urological Association does not recommend routine PSA 
screening in men aged ≥70 years.16 For the common practice model, where some men were 
assumed to continue screening after age 70, we used age-dependent screening rates from an 
empirical study of health behaviors in the U.S.: ages 70–74: 47%; 75–79: 44%; 80–84: 43%; 85+: 
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26%.7 As that study included all ages over 84 into a single category, we assumed the 26% rate of 
screening for this category applied to ages 85–90, with no screening above age 90. 
Biopsy criteria. The ERSPC study protocol stated that men with a positive screening test (PSA 
≥ 3.0 ng/mL) should be recommended for biopsy. The proportion of test-positive men who had 
evidence of cancer on biopsy was only 22.7%.14 In common urologic clinical practice, patients with 
elevated PSA are evaluated for benign disease and subject to repeat PSA testing before the decision 
to biopsy.17 We investigated how screening outcomes would change if men with elevated PSA were 
biopsied more selectively, based on clinical work-up. Instead of a PPV of 22.7% for biopsy after a 
positive PSA test, we applied a PPV of 40%, in line with U.S. clinical cohorts,18 for both the 
“recommended good practice” model and the “common practice” model. 
Active surveillance (AS). Recent data clearly indicate that not all men with PC need 
immediate treatment, and low-risk tumors can be safely managed by the approach known as active 
surveillance, with repeat biopsy and routine monitoring of the disease.19 Several guideline groups, 
such as the National Comprehensive Cancer Network, now recommend AS for low-risk PC.17 We 
investigated how QALYs were affected if men with low-risk disease (clinical stage T1, Gleason score 
6) were enrolled in AS. In the base model, AS usage depended on age, and averaged 30% across all 
men with low-risk tumors. For cumulative proportions of men leaving AS each year, we used data 
from Klotz’s series: year 1: 8%, year 2: 16%, year 3: 20%, year 4: 24%, year 5: 28%, year 6: 29%, and 
year 7: 30%.19 For the recommended good practice model, we applied a 90% rather than a 100% AS 
rate to men with low-risk disease, given that there may be clinical reasons to treat some low-risk 
men. For the common practice model, we applied an AS rate of 9.2% for men with low-risk disease, 
obtaining this estimate from the Cancer of the Prostate Strategic Urologic Research Endeavor 
(CaPSURE) registry 1990–2008, and also reflecting what has been practice for many years.9  
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High-volume centers. There is a considerable literature on the volume-outcome relationship, 
suggesting decreased complications and side-effects and improved outcomes for patients treated 
by high-volume providers.20-23 Shifting treatment trends so that more patients are treated by high-
volume surgeons could, therefore, possibly improve cancer control and decrease complications. 
There have been widespread calls for “regionalization”24; that is, increasing the proportion of 
patients treated at high-volume centers.25 We investigated how QALYs were affected if impotence 
and incontinence rates after RP were in line with rates seen at high-volume centers.26 The MISCAN 
model used a representative, multiregional, U.S. cohort as the source for estimates of overall sexual 
problems and urinary leakage problems at 24 months post-RP, taking baseline functioning into 
account.27 The base model assumed 30% overall sexual bother, 6% urinary bother, and 0% bowel 
bother post-RP.3 Although different rates were used for RT (20% sexual, 5% urinary, and 8% bowel 
bother), when multiplied with utilities, total utility ended up being similar for the two treatment 
modalities. These estimates may seem lower than many reported in the literature because they are 
marginal—that is, they take into account that some men would have dysfunction without surgery/ 
RT. Also, these estimates reflect bother not function, and not all men experiencing dysfunction 
report lowered utility.  
Estimates for functional outcomes after RP for surgeons at a high-volume center were 
derived from empirical data using case-mix-adjusted outcomes,26, giving rates of sexual and leakage 
problems of 19% and 5%, respectively.  
 
Sensitivity analysis 
A sensitivity analysis was performed, comparing QALYs gained between the 3 models. In an attempt 
to reflect the effect of the different strategies on a population level, rather than an individual level, 
we varied the utility estimates (more vs less extreme) by about half those previously published.3 
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We compared 5 different scenarios per model using different combinations of utilities for screening 
procedures versus treatment and terminal illness, ie, reflecting varying population-level trade-offs 
for tolerability of screening procedures versus down-stream consequences.  
Since the use of AS for men with low-risk disease has increased over the past years, another 
sensitivity analysis was performed, with a 34% AS rate, as reported in a recent update from the 
CaPSURE registry for the time period 2008–2013.28 
 
RESULTS 
Effect of modeling on QALYs 
Table 2 shows quality-adjusted effects of the 3 screening models, compared to no screening, given 
various health states. The recommended good practice model displayed favorable effects at the 
biopsy stage. Compared to the base model, the good practice model had more QALYs lost in the AS 
health state due to its increased AS rate (3.2 vs. 9.7 QALYs per 1000 men); however, this was 
balanced by fewer QALYs lost from side-effects after RT and RP. The opposite was true for the 
common practice model, with few QALYs lost for AS, but substantial losses in QALYs due to the 
higher rate of treatment with RT and RP. 
 The predicted effects of the screening approaches are shown in Table 3. Compared to the 
base model, recommended good practice led to an improvement in QALYs gained, from 56 to 74, 
largely related to increased use of AS. This approach also substantially reduced the number of 
biopsies performed, from 605 to 407 per 1000 men. In contrast, common practice with screening 
up to age 90 years and with a 9.2% AS rate, led to 78 life-years gained but only 19 QALYs gained. 
This is more than a 75% relative reduction in QALYs gained from unadjusted life-years gained. Of 
the QALYs lost by following common practice compared to recommended good practice, about 24 
were related to overtreatment of low-risk disease, 34 due to screening older men, and 3 due to 
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treatment at low-volume centers (Table 4). Note that these figures do not add up to the 55 QALY 
difference between common practice and recommended good practice because of interaction 
effects, such as the impact of overtreatment in older men.  
In a sensitivity analysis varying the more and less extreme utility estimates in an attempt to 
reflect the effect on QALYs of the different strategies at a population level, did not show 
recommended good practice leading to worse outcomes than the base or common practice models 
(Supplementary material). 
Increasing the use of AS to 34%, to reflect more contemporaneous rates, yielded an overall 
30 QALYs gained for current practice compared to 74 QALYs for recommended good practice. 
  
DISCUSSION 
This study examined the effect upon QALYs of widespread implementation of 4 widely-accepted 
screening and treatment recommendations, compared to common clinical practice. 
Microsimulation modeling showed that care following the good practice recommendations – 
restricting screening in elderly men, selective biopsy, AS for low risk tumors and preferential 
referral to high-volume centers – led to a large improvement in QALYs gained per 1000 men, up to 
74 from 56 for the base model. In contrast, common screening and treatment practice was 
estimated to lead to only 19 QALYs gained, translating into a more than 75% relative loss in 
potential QALYs gained.  
Naturally, any modeling study is only as good as the model used. The MISCAN model has 
been shown to adequately predict PC incidence and PC-specific mortality in the Netherlands.3 
When applied to the U.S. population and compared to other models, differences are relatively 
minor (eg, lead time of 7.9 vs. 6.9 years). In comparison with 2 other models, MISCAN may be 
conservative, that is, may overestimate some screening harms.29 We have also previously argued 
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that the European data may underestimate the benefits of screening due to sub-optimal treatment 
efficacy in the ERSPC, where both radiation doses and surgeon volumes were much lower than 
would be optimal.30 Note that we did not include higher cure rates associated with referral to high-
volume centers in our “recommended good practice” model, perhaps underestimating the benefits 
for more regionalized care. Furthermore, the differences in urinary and sexual problems between 
standard care and care at high-volume centers were relatively modest in our model: 1% and 11%, 
respectively, in absolute terms. Again, this may lead to some underestimation of the effects of 
regionalized treatment. 
There has been considerable recent interest in the use of risk-stratified methods of 
evaluating men with elevated PSA-levels before biopsy, such as reflex blood tests or 
multiparametric magnetic resonance imaging. The PPV associated with these tests is likely even 
higher than the 40% figure used in our models. The QALYs gained with recommended good practice 
may, therefore, be a slight underestimation. However, we do not expect this to make a large 
difference to our findings as the near 20-point increase in PPV used in the main analysis led to only 
a minor improvement in QALYs gained (+1.2 QALYs).  
 There is some evidence that current practice is changing. Across community-based urology 
practices in Michigan, half of men with low-risk PC now receive initial AS.31 We expect there will be 
more pronounced changes throughout the U.S. in the near future. Changing the use of AS to 34%, 
as reported in the most recent update from the CaPSURE registry,28 did increase overall QALYs 
gained from 19 to 30. These are promising signs that changes in urologic practice will make a large 
difference to quality-of-life outcomes of screening. 
There is also evidence that screening practices in older men have been changing for the 
better. For instance, incidence data from SEER have indicated that the age-, race- and ethnicity-
adjusted rate of early-stage PC among men ≥75 fell from 443 to 330 per 100,000 (−25.4%; p<0.001) 
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between 2007 and 2009.32 While encouraging, these changes go only a small way toward the major 
shift in screening and treatment practices needed for U.S. practice to be compliant with good 
practice recommendations. 
 Critics of PSA screening claim that it has little benefit and causes significant harm.  This may 
be the case as PSA screening is currently implemented in the US, but does not take into account the 
potential benefit of screening that follows good practice recommendations. Addressing the 
problems of screening in older men and aggressive treatment of low-risk disease might be expected 
to strongly increase the benefit of PSA screening.  
 A limitation of the present study is that results based on the MISCAN model are relevant for 
Caucasian men and may not apply to men of other ethnicities.  
 
CONCLUSIONS 
Common practices for PSA screening and subsequent PC treatment are associated with 
considerable harm and moderate benefit. Changing practices to conform to established 
recommendations would lead to an estimated 4-fold increase in the net benefit of screening. 
 
  
15 
 
REFERENCES 
1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the 
European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. 
Lancet. 2014;384:2027–35.  
2. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive 
Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–34.  
3. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen 
screening. N Engl J Med. 2012;367:595–605.  
4. Carlsson S, Vickers AJ, Roobol M, et al. Prostate cancer screening: facts, statistics, and 
interpretation in response to the U.S. Preventive Services Task Force Review. J Clin Oncol. 
2012;30:2581–4.  
5. Vickers A, Carlsson S, Laudone V, and Lilja H. It Ain't What You Do, It's the Way You Do It: Five 
Golden Rules for Transforming Prostate-Specific Antigen Screening. Eur Urol. 2014;66:188–90. 
6. Vickers AJ, Sjoberg DD, Ulmert D, et al. Empirical estimates of prostate cancer overdiagnosis by 
age and prostate-specific antigen. BMC Med. 2014;12:26.  
7. Drazer MW, Huo D, Schonberg MA, et al. Population-based patterns and predictors of prostate-
specific antigen screening among older men in the United States. J Clin Oncol. 2011;29:1736–43.  
8. Drazer MW, Prasad SM, Huo D, Razmaria A, Eggener SE. National trends in prostate cancer 
screening among older American men with limited 9-year life expectancies: Evidence of an 
increased need for shared decision making. Cancer. 2014;120:1491–8. 
9. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of 
localized prostate cancer. J Clin Oncol. 2010;28:1117–23.  
10. Savage CJ, Vickers AJ. Low annual caseloads of United States surgeons conducting radical 
prostatectomy. J Urol. 2009;182:2677–2679.  
11. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in 
early prostate cancer. N Engl J Med. 2011;364:1708–17.  
12. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of 
clinically localized prostate cancer. JAMA. 2005;293:2095–101.  
13. Institute for Clinical Research and Health Policy Studies. The Cost-Effectiveness Analysis 
Registry. Boston: Tufts Medical Center, Center for the Evaluation of Value and Risk in Health. 
Available at: http://www.cearegistry.org 
14. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a 
randomized European study. N Engl J Med. 2009;360:1320–8.  
15. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N 
Engl J Med. 2012;366:981–90.  
16. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J 
Urol. 2013;190:419–26.  
16 
 
17. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN 
Guidelines) – Prostate Cancer Early Detection, version 2.2015. Available at: 
http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf  
18. Vickers AJ, Cronin AM, Roobol MJ, et al. The relationship between prostate-specific antigen and 
prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res. 2010;16:4374–81. 
19. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of 
a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–31.  
20. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J 
Med. 2002;346:1138–44.  
21. Vickers AJ, Bianco FJ, Serio AM, et al. The surgical learning curve for prostate cancer control 
after radical prostatectomy. J Natl Cancer Inst. 2007;99:1171–7.   
22. Trinh QD, Bjartell A, Freedland SJ, et al. A systematic review of the volume-outcome relationship 
for radical prostatectomy. Eur Urol. 2013;64:786–98.  
23. Eastham JA. Do high-volume hospitals and surgeons provide better care in urologic oncology? 
Urol Oncol. 2009;27:417–21.  
24. Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation 
between surgical volume and mortality. N Engl J Med. 1979;301:1364–1369.  
25. Milstein A, Galvin RS, Delbanco SF, Salber P, Buck CR Jr. Improving the safety of health care: The 
Leapfrog Initiative. Eff Clin Pract. 2000;6:313–316.  
26. Vickers A, Savage C, Bianco F, et al. Cancer control and functional outcomes after radical 
prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a 
single cancer center. Eur Urol. 2011;59:317–22.  
27. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among 
prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.  
28. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 
1990-2013. JAMA. 2015;314:80–2.  
29. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen 
screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374–83.  
30. Vickers AJ, Lilja H. Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol. 
2009;6:301–3.  
31. Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC; Michigan Urological Surgery 
Improvement Collaborative. Contemporary Use of Initial Active Surveillance Among Men in 
Michigan with Low-risk Prostate Cancer. Eur Urol. 2015;67:44–50. 
32. Howard DH. Declines in prostate cancer incidence after changes in screening recommendations. 
Arch Intern Med. 2012;172:1267–8.  
17 
 
Table 1. Parameters Assigned to 3 MISCAN-based Models of PSA Screening and Treatment 
 
Base Model 
(Heijnsdijk et al3) 
Recommended Good  
Practice Model 
Common Practice Model 
 Parameter Source Parameter Source Parameter Source 
1. Ages of men 
screened 
55–69 years Schröder et al14 55–69 years Schröder et 
al14 
55–90 years Drazer et al7 
2. PPV of 
biopsy 
22.7% Schröder et al14 40% Vickers et 
al18 
40% Vickers et al18 
3. Use of AS AS rates 
depending on age, 
T stage and 
Gleason score as 
in ERSPC for both 
low-risk and 
non−low-risk PC; 
about 30% for 
low-risk 
ERSPC data  AS rates for non−low-
risk PC same as base 
model 
ERSPC data AS rates for non−low-
risk PC same as base 
model 
ERSPC data 
90% AS for men with 
low-risk tumors 
Assumption 
 
9.2% AS for men with 
low-risk tumors 
Cooperberg et 
al9 
 
4. Rate of side-
effects 
Population-based 
rates: 
6% urinary 
leakage problems, 
30% overall 
sexuality 
problems 
Sanda et al27 
 
Rates as seen in high-
volume centers: 
5% urinary leakage 
problems, 
19% overall sexuality 
problems 
Vickers et 
al26 
Population-based rates: 
6% urinary leakage 
leaking problems, 
30% overall sexuality 
problems 
Sanda et al27 
 
Abbreviations: AS, active surveillance; ERSPC, European Randomized Study of Screening for Prostate Cancer; MISCAN, Microsimulation 
Screening Analysis; PC, prostate cancer; PPV, positive predictive value; PSA, prostate-specific antigen.   
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Table 2. QALYs Gained By the 3 Screening and Treatment Models At Various Health States  
 
 Utility Estimates Quality of Life Adjustmenta 
No. of life-years 
Health Stateb Base case More 
extreme 
Less 
extreme 
Base modelc Recommended 
good practice 
Common 
practice  
Screening  0.99 0.99 1 −1.6 −1.6 −1.4 
Biopsy 0.90 0.885 0.94 −1.7 −0.5 −1.6 
Cancer diagnosis 0.80 0.775 0.85 −0.7 −0.7 −2.1 
Radiotherapy 
   At 2 months after procedure 
   At >2–12 months 
 
0.73 
0.78 
 
0.72 
0.695 
 
0.82 
0.83 
 
−0.2 
−0.9 
 
−0.0 
−0.2 
 
−2.7 
−11.0 
Radical prostatectomy 
   At 2 months after procedure 
   At >2-12 months 
 
0.67 
0.77 
 
0.615 
0.735 
 
0.785 
0.84 
 
−2.0 
−6.9 
 
−0.6 
−2.1 
 
−3.9 
−13.7 
Active surveillance 0.97 0.91 0.985 −3.2 −9.7 −1.4 
Post-recovery periodd 
(1–10 years after treatment)  
      
   Overdiagnosise 0.95d,f 0.94 0.975 −10.8 −5.6 −24.8 
   No overdiagnosis 0.95d,f 0.94 0.975 −5.5 5.5 −19.8 
Palliative therapy 0.60 0.73 0.42 14.1 14.2 18.4 
Terminal illness 0.40 0.40 0.32 2.6 2.6 3.2 
Total number of life-years gained Full model Full model Full model 73 73 78 
Total number of QALYs gained Full model Full model Full model 56 74 19 
 
Abbreviation: QALYs, quality-adjusted life-years. 
aNumbers are over the lifetimes of 1000 men aged 0–100. Minus sign indicates number of years to be subtracted from the life-years gained in 
order to get the QALYs gained. 
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b For a complete list of sources of the utility values and the duration of temporary health states, see Heijnsdijk et al.3 The more and less 
extreme utilities used for the sensitivity analysis are assumed to be half those previously reported, to reflect the effects of a policy on a 
population level, rather than the effects on the individual level. 
cThe difference in life-years for each health state has been multiplied by the utility loss to calculate the adjustment for quality of life. 
dThe following utilities translate into an aggregated utility of 0.95: urinary leakage, 0.83; bowel problems, 0.71; and sexuality problems, 0.89. 
e Overdiagnosis implies diagnosis of prostate cancer, which in a situation without screening would not have been clinically diagnosed within the 
lifespan of a typical man. 
f0.96 for the recommended good practice model. 
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Table 3. Predicted Effects of the 3 Screening and Treatment Models, Compared to No Screeninga 
 
  No Screening Base Model Recommended 
Good Practice  
Common 
Practice  
Biopsies performed 313 605  407 595b 
Negative biopsies 201 448 250 359 
Cancers diagnosed 112 157 157 236 
Relative reduction in prostate 
cancer−specific mortality 
- 37% 37% 41% 
Life-years gained - 73 73 78 
QALYs gained - 56 74 19 
Relative reduction in life-years gained 
after adjustment for quality of life 
- 23% –1% 76% 
 
Abbreviations: QALYs, quality-adjusted life-years. 
aNumbers are over the lifetime of 1000 men aged 0−100.  
bSome men undergo more than one biopsy. 
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Table 4. QALYs Gained/Lost By Different Aspects of Practice  
 
 Recommended Good Practice Common Practice 
Parameter Aspect of practice QALYsa Aspect of practice QALYsa 
1. Age for screening Limit screening in older 
men 
Same as base model Widespread screening 
of older men 
34.2 (–21.8) 
2. Biopsy criteria Restrictive biopsy 
criteria 
57.2 (+1.2) Restrictive biopsy 
criteria 
57.2 (+1.2) 
3. AS AS for most low-risk 
cancers 
73.2 (+17.2) Little use of AS 49.1 (–6.9) 
4. Regionalization Most treatment at 
high-volume centers 
59.3 (+3.3) Much treatment at low-
volume centers 
Same as base model 
Total All four of the above 
factors 
74.0 (+18.0) All four of the above 
factors 
19.0 (–37.0) 
 
Abbreviations: AS, active surveillance; QALYs, quality-adjusted life-years. 
aNumber in parentheses indicates incremental/decremental effect on QALYs as compared to base model’s 56.0 QALYs gained. 
 
